GC Biopharma said on the 9th that it took part in the "Korea 100-day mission tabletop exercise" jointly organized by the Coalition for Epidemic Preparedness Innovations (CEPI), the Korea Disease Control and Prevention Agency, the Ministery of Food and Drug Safety, and the International Vaccine Institute (IVI) on the 5th and 6th.
The exercise focused on checking, through a scenario-based approach, whether the entire process of vaccine development, authorization, production, and supply could be completed within 100 days in the event of a future pandemic. The goal was to prearrange a decision-making framework among the government, international organizations, and vaccine manufacturers to reduce potential delays in response during an actual crisis.
GC Biopharma participated as a manufacturer capable of performing all preclinical-to-clinical steps for developing mRNA medicines and assessed its vaccine development and production capabilities using its platform. Discussions were also held on flexibly applying clinical trial progress and authorization procedures under a pandemic scenario.
The company said the exercise confirmed the potential for a faster response within a government collaboration framework. It added that it is also reviewing the possibility of vaccine development and procurement cooperation with international organizations in the future.
Lee Jae-woo, head of development at GC Biopharma, said, "We plan to continue participating in the public-private collaboration framework."